Finally, the interest of a triple antiplatelet therapy (with cilostazol or another molecule) in patients with a very high risk of thrombosis will need to be evaluated. Gregory Ducrocq is a ...

The improvement of our knowledge on the pharmacodynamics of antiplatelet drugs enables the tailoring of the most appropriate antithrombotic therapy to the individual patient and risk situation in ...